all-trans-4-Oxoretinoic acid (all-trans 4-Keto Retinoic Acid)
(Synonyms: 4-KETO全反式维甲酸,all-trans 4-Keto Retinoic Acid) 目录号 : GC31420An active metabolite of all-trans retinoic acid
Cas No.:38030-57-8
Sample solution is provided at 25 µL, 10mM.
4-oxo Retinoic acid is an active metabolite of the vitamin A metabolite and retinoic acid receptor (RAR) ligand all-trans retinoic acid .1 It is formed from all-trans retinoic acid by several cytochrome P450 (CYP) isoforms, including CYP1A1, CYP3A7, and CYP26A1.2,3 4-oxo Retinoic acid binds to RARα, RARβ, and RARγ (IC50s = 59, 50, and 142 nM, respectively, in radioligand binding assays) and induces expression of a luciferase reporter in COS-7 cells expressing RARα, RARβ, or RARγ (EC50s = 33, 8, and 89 nM, respectively).1 It increases protein levels of cytokeratin 7 (CK-7) and CK-19 in human epidermal keratinocytes when used at a concentration of 1 ?M.4 4-oxo Retinoic acid (10-1,000 nM) inhibits the proliferation of MCF-7 breast cancer cells.5 It is teratogenic to zebrafish embryos (EC50 = 8.1 nM).6
1.Idrest, N., Marill, J., Flexor, M.A., et al.Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomersJ. Biol. Chem.277(25)31491-31498(2002) 2.Marill, J., Cresteil, T., Lanotte, M., et al.Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolitesMol. Pharmacol.58(6)1341-1348(2000) 3.Thatcher, J.E., Buttrick, B., Shaffer, S.A., et al.Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylaseMol. Pharmacol.80(2)228-239(2011) 4.Baron, J.M., Heise, R., Blaner, W.S., et al.Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitroJ. Invest. Dermatol.125(1)143-153(2005) 5.Van heusden, J., Wouters, W., Ramaekers, F.C.S., et al.All-trans-retinoic acid metabolites significantly inhibit the proliferation of MCF-7 human breast cancer cells in vitroBr. J. Cancer77(1)26-32(1998) 6.Pípal, M., Novák, J., Rafajová, A., et al.Teratogenicity of retinoids detected in surface waters in zebrafish embryos and its predictability by in vitro assaysAquat. Toxicol.246106151(2022)
Cas No. | 38030-57-8 | SDF | |
别名 | 4-KETO全反式维甲酸,all-trans 4-Keto Retinoic Acid | ||
Canonical SMILES | CC(/C=C/C=C(/C=C/C1=C(C(CCC(C)1C)=O)C)C)=C\C(O)=O | ||
分子式 | C20H26O3 | 分子量 | 314.42 |
溶解度 | DMSO : 150 mg/mL (477.07 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.1805 mL | 15.9023 mL | 31.8046 mL |
5 mM | 0.6361 mL | 3.1805 mL | 6.3609 mL |
10 mM | 0.318 mL | 1.5902 mL | 3.1805 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet